The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases
Open accessAbstract
The identification of new bioactive compounds derived from medicinal plants with significant therapeutic properties has attracted considerable interest in recent years. Such is the case of the Tripterygium wilfordii, an herb used in Chinese medicine. Clinical trials performed so far using its root extracts have shown impressive therapeutic properties, but also revealed substantial gastrointestinal side-effects. The most promising bioactive compound obtained from Tripterygium wilfordii is celastrol. During the last decade, an increasing number of studies were published highlighting the medicinal usefulness of celastrol in diverse clinical areas. Here we systematically review the mechanism of action and the therapeutic properties of celastrol in inflammatory diseases, namely rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, osteoarthritis and allergy, as well as in cancer, neurodegenerative disorders and other diseases, such as diabetes, obesity, atherosclerosis and hearing loss. We will also focus in the toxicological profile and limitations of celastrol formulation, namely solubility, bioavailability and dosage issues that still limit its further clinical application and usefulness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death
Boje, K. M., & Arora, P. K. (1992) · Brain Research · doi:10.1016/0006-8993(92)91004-x · Cited by 944 · cited 1×
“Furthermore, the activated microglia-derived proinflammatory factors, ROS and NO, have long been believed to be involved with neuroinflammation in neurodegenerative diseases, including Parkinson and Alzheimer’s disease (171).”
BackgroundCell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Treatment of Obesity with Celastrol
Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015) · Cell · doi:10.1016/j.cell.2015.05.011 · Cited by 726 · cited 2×
“It can restore the leptin signaling in neurons by overexpressing anorexigenic peptides pro-opiomelanocortin (POMC) and/ or repressing orexigenic peptides [neuropeptide Y (NPY)/AgRP] (182, 183).”
BackgroundNeurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Allison, A. C., Cacabelos, R., Lombardi, V. R. M., Álvarez, X. A., & Vigo, C. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00192-0 · Cited by 376
Chadli, A., Felts, S. J., Wang, Q., Sullivan, W. P., Botuyan, M. V., Fauq, A., Ramirez-Alvarado, M., & Mer, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081018 · Cited by 94 · cited 1×
“have shown that celastrol inhibits p23, a HSP90 co-chaperon specific for steroid receptors, which is relevant for steroid-mediated cancers (88).”
BackgroundHafizi Abu Bakar, M., Kian Kai, C., Wan Hassan, W. N., Sarmidi, M. R., Yaakob, H., & Zaman Huri, H. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2601 · Cited by 91 · cited 1×
“Diabetes The exact mechanism underlying type 2 diabetes is still unclear despite the implication of processes such as mitochondrial dysfunction and inflammation (174).”
BackgroundZhao, J., Sun, Y., Shi, P., Dong, J.-N., Zuo, L.-G., Wang, H.-G., Gong, J.-F., Li, Y., Gu, L.-L., Li, N., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.03.033 · Cited by 80
Wu (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.600 · Cited by 59 · cited 13×
“Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.”
BackgroundInfluential
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Plant-derived anticancer agents: A green anticancer approach
Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.10.016 · Cited by 685
Celastrol in cancer therapy: Recent developments, challenges and prospects
Lim, H. Y., Ong, P. S., Wang, L., Goel, A., Ding, L., Li-Ann Wong, A., Ho, P. C.-L., Sethi, G., Xiang, X., & Goh, B. C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.030 · Cited by 118
Fan, N., Zhang, X., Zhao, W., Zhao, J., Luo, D., Sun, Y., Li, D., Zhao, C., Wang, Y., Zhang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73890 · Cited by 104
Moreira, H., Szyjka, A., Paliszkiewicz, K., & Barg, E. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6793957 · Cited by 55
Metadata
- Authors
- Cascão, R., Fonseca, J. E., & Moita, L. F.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2017-06-15
- Volume
- 4
- Pages
- 69-69
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2734811226
- Cited by
- 244
- References
- 11
- FWCI
- 29.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases. https://app.cochat.ai/papers/10.3389/fmed.2017.00069
- The paper
- Cascão, R., Fonseca, J. E., & Moita, L. F. (2017). Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases. Frontiers in Medicine. https://doi.org/10.3389/fmed.2017.00069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.